Abbott Laboratories
Stock Forecast, Prediction & Price Target
Abbott Laboratories (ABT) stock Price Target by analysts
Abbott Laboratories (ABT) stock Price Target by analysts
Average Price Target
$130.38
Potential downside: -0.86%
Abbott Laboratories price prediction
What is Abbott Laboratories stock analysts` prediction?
Abbott Laboratories stock forecast: Based on 8 Wall Street analysts` predicted price targets for Abbott Laboratories in the last 3 months, the avarage price target is $130.38, with a high forecast of $NaN. The average price target represents a -0.86% change from the last price of $131.51.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Abbott Laboratories stock Price Target by analysts
Full breakdown of analysts given Abbott Laboratories price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Adam Maeder Piper Sandler | 0% 0/2 | 11 months ago | $133 1.13% upside | $117.82 | StreetInsider | Previous targets (1) |
Lee Hambright Bernstein | 0% 0/2 | 11 months ago | $138 4.93% upside | $117.82 | TheFly | Previous targets (1) |
Vijay Kumar Evercore ISI | 33.33% 1/3 | 12 months ago | $128 -2.66% downside | $117.82 | StreetInsider | Previous targets (2) |
Marie Thibault BTIG | 0% 0/5 | 12 months ago | $139 5.69% upside | $117.82 | StreetInsider | Previous targets (4) |
Matthew Taylor Jefferies | 0% 0/2 | 12 months ago | $125 -4.95% downside | $117.82 | StreetInsider | Previous targets (1) |
Suraj Kalia Oppenheimer | 0% 0/1 | 12 months ago | $130 -1.14% downside | $114.3 | Benzinga | Previous targets (0) |
Shagun Singh RBC Capital | 0% 0/3 | 12 months ago | $130 -1.14% downside | $113.36 | TheFly | Previous targets (2) |
Charles Minervino Susquehanna | 0% 0/1 | 12 months ago | $120 -8.75% downside | $114.3 | Benzinga | Previous targets (0) |
Adam Maeder Piper Sandler | 0% 0/2 | about 1 year ago | $131 -0.38% downside | $114.88 | TheFly | Previous targets (1) |
Jonathan Atkin RBC Capital | 0% 0/1 | about 1 year ago | $345 162.33% upside | $113.48 | Benzinga | Previous targets (0) |
Scott Fortune Roth Capital | 0% 0/1 | about 1 year ago | $50 -61.98% downside | $113.48 | Benzinga | Previous targets (0) |
Matthew Taylor Jefferies | 0% 0/2 | about 1 year ago | $120 -8.75% downside | $112.23 | StreetInsider | Previous targets (1) |
Joanne Wuensch Citigroup | 0% 0/2 | about 1 year ago | $127 -3.42% downside | $111.39 | TheFly | Previous targets (1) |
Jayson Bedford Raymond James | 0% 0/3 | about 1 year ago | $127 -3.42% downside | $104.68 | Benzinga | Previous targets (2) |
Joanna Wiensch Citigroup | 0% 0/1 | about 1 year ago | $119 -9.51% downside | $104.68 | Benzinga | Previous targets (0) |
Vijay Kumar Evercore ISI | 33.33% 1/3 | about 1 year ago | $120 -8.75% downside | $103.2 | TheFly | Previous targets (2) |
Marie Thibault BTIG | 0% 0/5 | over 1 year ago | $135 2.65% upside | $102.99 | StreetInsider | Previous targets (4) |
David Roman Goldman Sachs | 0% 0/1 | over 1 year ago | $121 -7.99% downside | $100.73 | StreetInsider | Previous targets (0) |
Matt Miksic Barclays | 0% 0/1 | over 1 year ago | $140 6.45% upside | $107.07 | StreetInsider | Previous targets (0) |
Lee Hambright Bernstein | 0% 0/2 | over 1 year ago | $133 1.13% upside | $105.27 | TheFly | Previous targets (1) |
Shagun Singh RBC Capital | 0% 0/3 | over 1 year ago | $125 -4.95% downside | $105.9 | StreetInsider | Previous targets (2) |
Unknown Morgan Stanley | N/A | over 2 years ago | $133 1.13% upside | $111.37 | Benzinga | N/A |
Unknown Citigroup | N/A | almost 3 years ago | $125 -4.95% downside | $107.51 | Benzinga | N/A |
Shagun Singh RBC Capital | 0% 0/3 | about 3 years ago | $132 0.37% upside | $109.78 | Pulse 2.0 | Previous targets (2) |
Unknown UBS | N/A | about 3 years ago | $128 -2.66% downside | $109.09 | Benzinga | N/A |
Unknown RBC Capital | N/A | about 3 years ago | $132 0.37% upside | $108.99 | Benzinga | N/A |
Unknown Citigroup | N/A | about 3 years ago | $123 -6.47% downside | $108.23 | Benzinga | N/A |
Unknown Stifel Nicolaus | N/A | about 3 years ago | $126 -4.18% downside | $108.43 | Benzinga | N/A |
Unknown BTIG | N/A | about 3 years ago | $126 -4.18% downside | $108.36 | Benzinga | N/A |
Unknown Raymond James | N/A | about 3 years ago | $117 -11.03% downside | $105.71 | Benzinga | N/A |
Marie Thibault BTIG | 0% 0/5 | about 3 years ago | $130 -1.14% downside | $109.45 | Pulse 2.0 | Previous targets (4) |
Marie Thibault BTIG | 0% 0/5 | over 3 years ago | $130 -1.14% downside | $109.45 | Pulse 2.0 | Previous targets (4) |
Jayson Bedford Raymond James | 0% 0/3 | over 3 years ago | $135 2.65% upside | $119.64 | Pulse 2.0 | Previous targets (2) |
Marie Thibault BTIG | 0% 0/5 | over 3 years ago | $140 6.45% upside | $123.8 | TipRanks Contributor | Previous targets (4) |
Larry Biegelsen Wells Fargo | 0% 0/1 | over 3 years ago | $150 14.05% upside | $120.04 | Pulse 2.0 | Previous targets (0) |
Travis Steed Bank of America Securities | 0% 0/1 | over 3 years ago | $140 6.45% upside | $120.97 | Pulse 2.0 | Previous targets (0) |
Cecilia Furlong Morgan Stanley | 0% 0/1 | over 3 years ago | $151 14.82% upside | $122.41 | Pulse 2.0 | Previous targets (0) |
Jayson Bedford Raymond James | 0% 0/3 | over 3 years ago | $143 8.73% upside | $129.71 | Pulse 2.0 | Previous targets (2) |
Joanne Wuensch Citigroup | 0% 0/2 | almost 4 years ago | $154 17.10% upside | $135.08 | TheFly | Previous targets (1) |
Raj Denhoy Jefferies | 0% 0/1 | almost 4 years ago | $145 10.25% upside | $124.61 | StreetInsider | Previous targets (0) |
Rick Wise Stifel Nicolaus | 100% 1/1 | about 4 years ago | $130 -1.14% downside | $117.38 | StreetInsider | Previous targets (0) |
Amit Hazan Goldman Sachs | 100% 1/1 | over 4 years ago | $120 -8.75% downside | $104.61 | TheFly | Previous targets (0) |
Vijay Kumar Evercore ISI | 33.33% 1/3 | over 4 years ago | $136 3.41% upside | $121.24 | TipRanks | Previous targets (2) |
Abbott Laboratories Financial Estimates
Abbott Laboratories Revenue Estimates
Abbott Laboratories EBITDA Estimates
Abbott Laboratories Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $43.07B N/A | $43.65B 1.34% | $40.10B -8.11% | Avg: $44.72B Low: $44.52B High: $44.90B avg. 11.51% | Avg: $47.97B Low: $47.68B High: $48.29B avg. 7.26% | Avg: $51.41B Low: $51.09B High: $51.74B avg. 7.15% | Avg: $54.82B Low: $54.48B High: $55.18B avg. 6.63% |
Net Income
% change YoY
| $7.07B N/A | $6.93B -1.95% | $5.72B -17.45% | Avg: $7.18B Low: $6.19B High: $7.63B avg. 25.55% | Avg: $7.96B Low: $7.27B High: $8.85B avg. 10.81% | Avg: $10.78B Low: $10.69B High: $10.87B avg. 35.44% | Avg: $11.83B Low: $11.73B High: $11.93B avg. 9.70% |
EBITDA
% change YoY
| $10.74B N/A | $10.69B -0.49% | $10.60B -0.85% | Avg: $10.61B Low: $10.56B High: $10.65B avg. 0.08% | Avg: $11.38B Low: $11.31B High: $11.46B avg. 7.26% | Avg: $12.20B Low: $12.12B High: $12.28B avg. 7.15% | Avg: $13.01B Low: $12.92B High: $13.09B avg. 6.63% |
EPS
% change YoY
| $3.97 N/A | $3.94 -0.75% | $3.3 -16.24% | Avg: $4.01 Low: $3.54 High: $4.37 avg. 21.66% | Avg: $4.61 Low: $4.16 High: $5.06 avg. 14.86% | Avg: $6.17 Low: $6.12 High: $6.22 avg. 33.71% | Avg: $6.77 Low: $6.71 High: $6.82 avg. 9.70% |
Operating Expenses
% change YoY
| $16.11B N/A | $16.14B 0.22% | $15.65B -3.05% | Avg: $12.34B Low: $12.28B High: $12.39B avg. -21.16% | Avg: $13.24B Low: $13.15B High: $13.32B avg. 7.26% | Avg: $14.18B Low: $14.09B High: $14.28B avg. 7.15% | Avg: $15.12B Low: $15.03B High: $15.22B avg. 6.63% |
FAQ
What is Abbott Laboratories stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 20.38% in 2025-2028.
We have gathered data from 14 analysts. Their low estimate is 6.19B, average is 7.18B and high is 7.63B.
What is Abbott Laboratories stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.14% in 2025-2028.
We have gathered data from 18 analysts. Their low revenue estimate is $44.52B, average is $44.72B and high is $44.90B.
What is Abbott Laboratories stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.98% in 2025-2028.
We have gathered data from 14 analysts. Their low earnings per share estimate is $3.54, average is $4.01 and high is $4.36.
What is the best performing analyst?
In the last twelve months 8 analysts have been covering Abbott Laboratories stock. The most successful analyst is Adam Maeder.